{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T15:30:54Z","timestamp":1759073454785},"reference-count":38,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["schres-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.schres.2015.03.025","type":"journal-article","created":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T13:56:34Z","timestamp":1428760594000},"page":"149-154","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Challenging the need for sustained blockade of dopamine D2 receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study"],"prefix":"10.1016","volume":"164","author":[{"given":"Takashi","family":"Tsuboi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takefumi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert R.","family":"Bies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Remington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce G.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Mimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.schres.2015.03.025_bb0005","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","article-title":"A depression rating scale for schizophrenics","volume":"3","author":"Addington","year":"1990","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.03.025_bb0010","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2015.03.025_bb0015","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/0091270007310385","article-title":"Sex, race, and smoking impact olanzapine exposure","volume":"48","author":"Bigos","year":"2008","journal-title":"J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.schres.2015.03.025_bb0020","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1176\/ajp.132.12.1237","article-title":"Overview: maintenance therapy in psychiatry: I. Schizophrenia","volume":"132","author":"Davis","year":"1975","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2015.03.025_bb0025","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archpsyc.1976.01770060086012","article-title":"The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance","volume":"33","author":"Endicott","year":"1976","journal-title":"Arch. Gen. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2015.03.025_bb0030","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects","volume":"49","author":"Farde","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2015.03.025_bb0035","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2125.2008.03276.x","article-title":"Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study","volume":"66","author":"Feng","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.schres.2015.03.025_bb0040","series-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"issue":"416","key":"10.1016\/j.schres.2015.03.025_bb0045","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1034\/j.1600-0447.107.s416.5.x","article-title":"The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia","author":"Haro","year":"2003","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"8","key":"10.1016\/j.schres.2015.03.025_bb0050","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.4088\/JCP.12m07638","article-title":"A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia","volume":"73","author":"Ikai","year":"2012","journal-title":"J. Clin. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2015.03.025_bb0055","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/archpsyc.1995.03950210050010","article-title":"Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients","volume":"52","author":"Jeste","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2015.03.025_bb0060","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2015.03.025_bb0065","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.schres.2015.03.025_bb0075","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1600-0447.1999.tb00972.x","article-title":"A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms","volume":"99","author":"Lemmens","year":"1999","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2015.03.025_bb0080","first-page":"CD008016","article-title":"Maintenance treatment with antipsychotic drugs for schizophrenia","volume":"5","author":"Leucht","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.schres.2015.03.025_bb0085","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.pnpbp.2011.12.013","article-title":"Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study","volume":"37","author":"Mizuno","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2015.03.025_bb0090","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/JCP.0b013e3182979a0a","article-title":"Estimated dopamine D(2) receptor occupancy and remission in schizophrenia: analysis of the CATIE data","volume":"33","author":"Moriguchi","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"issue":"Suppl. 3","key":"10.1016\/j.schres.2015.03.025_bb0095","first-page":"133","article-title":"A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables","volume":"10","author":"Naber","year":"1995","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2015.03.025_bb0100","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1176\/ajp.152.2.173","article-title":"D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate","volume":"152","author":"Nyberg","year":"1995","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2015.03.025_bb0105","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1176\/appi.ajp.163.3.507","article-title":"Association between the CCR5 32-bp deletion allele and late onset of schizophrenia","volume":"163","author":"Rasmussen","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2015.03.025_bb0110","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.schres.2015.03.025_bb0115","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.4088\/JCP.09m05866yel","article-title":"\u201cExtended\u201d antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial","volume":"72","author":"Remington","year":"2011","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2015.03.025_bb0120","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/schbul\/sbr189","article-title":"Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data","volume":"39","author":"Sakurai","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.schres.2015.03.025_bb0125","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF01061728","article-title":"Estimation of population characteristics of pharmacokinetic parameters from routine clinical data","volume":"5","author":"Sheiner","year":"1977","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.schres.2015.03.025_bb0130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"issue":"2\u20133","key":"10.1016\/j.schres.2015.03.025_bb0135","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.schres.2013.08.033","article-title":"Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience\/drug attitude in schizophrenia: an analysis of the CATIE data","volume":"150","author":"Takeuchi","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2015.03.025_bb0145","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.pnpbp.2013.05.010","article-title":"Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data","volume":"45","author":"Tsuboi","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2015.03.025_bb0150","series-title":"23rd Annual Meeting of the Japanese Society of Clinical Neuropsychopharmacology, Okinawa","article-title":"Predicting antipsychotic plasma concentration of olanzapine associated with dosage change: a population pharmacokinetic study","author":"Tsuboi","year":"2013"},{"key":"10.1016\/j.schres.2015.03.025_bb0185","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/JCP.0000000000000065","article-title":"Dose and dosing frequency of long-acting injectable antipsychotics: a systematic review of PET and SPECT data and clinical implications","volume":"34","author":"Uchida","year":"2014","journal-title":"J. Clin. Psychopharmacol"},{"issue":"8","key":"10.1016\/j.schres.2015.03.025_bb0165","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.4088\/JCP.v69n0811","article-title":"Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia","volume":"69","author":"Uchida","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2015.03.025_bb0170","doi-asserted-by":"crossref","first-page":"397","DOI":"10.4088\/JCP.08r04171","article-title":"Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms","volume":"70","author":"Uchida","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2015.03.025_bb0160","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/JGP.0b013e318198776d","article-title":"Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms","volume":"17","author":"Uchida","year":"2009","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2015.03.025_bb0180","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/clpt.2009.133","article-title":"Predicting age-specific dosing of antipsychotics","volume":"86","author":"Uchida","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.schres.2015.03.025_bb0195","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/schbul\/sbp149","article-title":"Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis","volume":"37","author":"Uchida","year":"2011","journal-title":"Schizophr. Bull."},{"issue":"4","key":"10.1016\/j.schres.2015.03.025_bb0200","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/JCP.0b013e3182214aad","article-title":"Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis","volume":"31","author":"Uchida","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2015.03.025_bb0205","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/JCP.0b013e318218d339","article-title":"Predicting dopamine D(2) receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis","volume":"31","author":"Uchida","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2015.03.025_bb0175","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/FTD.0b013e3182489a6f","article-title":"Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study","volume":"34","author":"Uchida","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.schres.2015.03.025_bb0155","series-title":"3rd Congress of the Asian College of Neuropsychopharmacology, Beijing","article-title":"Predicting dopamine D2 receptor occupancy following antipsychotic dose reduction: a pilot PET study","author":"Uchida","year":"2013"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996415001620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996415001620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T10:21:30Z","timestamp":1717842090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996415001620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":38,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0920996415001620"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2015.03.025","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenging the need for sustained blockade of dopamine D2 receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2015.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}